Optipharm.CO.LTD (153710) - Total Assets
Based on the latest financial reports, Optipharm.CO.LTD (153710) holds total assets worth ₩42.32 Billion KRW (≈ $28.68 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See 153710 book value for net asset value and shareholders' equity analysis.
Optipharm.CO.LTD - Total Assets Trend (2015–2024)
This chart illustrates how Optipharm.CO.LTD's total assets have evolved over time, based on quarterly financial data.
Optipharm.CO.LTD - Asset Composition Analysis
Current Asset Composition (December 2024)
Optipharm.CO.LTD's total assets of ₩42.32 Billion consist of 43.1% current assets and 56.9% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩10.40 Billion | 8.4% |
| Accounts Receivable | ₩1.20 Billion | 2.8% |
| Inventory | ₩1.98 Billion | 4.6% |
| Property, Plant & Equipment | ₩23.79 Billion | 54.9% |
| Intangible Assets | ₩295.01 Million | 0.7% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2015–2024)
This chart illustrates how Optipharm.CO.LTD's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Optipharm.CO.LTD stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Optipharm.CO.LTD's current assets represent 43.1% of total assets in 2024, an increase from 14.6% in 2015.
- Cash Position: Cash and equivalents constituted 8.4% of total assets in 2024, up from 3.5% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2015.
- Asset Diversification: The largest asset category is property, plant & equipment at 54.9% of total assets.
Optipharm.CO.LTD Competitors by Total Assets
Key competitors of Optipharm.CO.LTD based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Revvity Inc.
NYSE:RVTY
|
USA | $12.17 Billion |
|
Sonic Healthcare Ltd
AU:SHL
|
Australia | AU$17.03 Billion |
|
Fleury S.A.
SA:FLRY3
|
Brazil | R$13.22 Billion |
|
Shanghai Labway Clinical Laboratory Co Ltd
SHE:301060
|
China | CN¥2.43 Billion |
|
Genoray Co. Ltd
KQ:122310
|
Korea | ₩125.67 Billion |
|
Bcal Diagnostics Ltd
AU:BDX
|
Australia | AU$7.17 Million |
|
Avricore Health Inc
V:AVCR
|
Canada | CA$1.33 Million |
|
Integral Diagnostics Ltd
AU:IDX
|
Australia | AU$1.43 Billion |
Optipharm.CO.LTD - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.29 | 1.64 | 4.65 |
| Quick Ratio | 1.08 | 1.45 | 4.52 |
| Cash Ratio | 0.00 | 1.16 | 0.00 |
| Working Capital | ₩3.74 Billion | ₩7.92 Billion | ₩20.15 Billion |
Optipharm.CO.LTD - Advanced Valuation Insights
This section examines the relationship between Optipharm.CO.LTD's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.10 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 10.3% |
| Total Assets | ₩43.32 Billion |
| Market Capitalization | $51.60 Million USD |
Valuation Analysis
Below Book Valuation: The market values Optipharm.CO.LTD's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Optipharm.CO.LTD's assets grew by 10.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Optipharm.CO.LTD (2015–2024)
The table below shows the annual total assets of Optipharm.CO.LTD from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩43.32 Billion ≈ $29.36 Million |
+10.30% |
| 2023-12-31 | ₩39.28 Billion ≈ $26.62 Million |
-4.63% |
| 2022-12-31 | ₩41.18 Billion ≈ $27.91 Million |
+0.03% |
| 2021-12-31 | ₩41.17 Billion ≈ $27.90 Million |
-0.37% |
| 2020-12-31 | ₩41.32 Billion ≈ $28.00 Million |
-0.96% |
| 2019-12-31 | ₩41.72 Billion ≈ $28.27 Million |
-2.16% |
| 2018-12-31 | ₩42.64 Billion ≈ $28.90 Million |
+114.87% |
| 2017-12-31 | ₩19.84 Billion ≈ $13.45 Million |
-3.55% |
| 2016-12-31 | ₩20.58 Billion ≈ $13.94 Million |
+18.17% |
| 2015-12-31 | ₩17.41 Billion ≈ $11.80 Million |
-- |
About Optipharm.CO.LTD
Optipharm.CO.,LTD operates as a biomedical solution provider in South Korea. It also engages in animal disease diagnosis, animal medicine, bacteriophage, Medipig, xenogenic organs, VLP vaccines, xenotransplantation, and other optipharm products, as well as veterinary drug for feed additives and laboratory animal Medipig business. The company was formerly known as Optiparm Solution Co., Ltd. and c… Read more